Antibody Genetics Immune Response Scientist 
Drug Discovery World
MAY 6, 2024
Immune B cells could be used to develop cancer targeting immunotherapies, following new research by scientists at The Institute of Cancer Research, London, the University of Oxford and University of Cambridge. B cells are similar to T cell in that they work as part of the immune system to help fight infections as well as cancer.
XTalks
JANUARY 11, 2023
It also seems to be very adept at evading the immune response owing to a plethora of mutations that makes it immune evasive. “It The new subvariant has also been dubbed “Kraken” by some scientists. on the horizon as scientists say the virus appears to be rapidly evolving , mutating faster than most viruses.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
FEBRUARY 28, 2024
Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers. In glioblastoma, as with many other highly recurrent cancers, tumour cells that escape treatment develop multiple genetic adaptations that allow them to proliferate.
pharmaphorum
FEBRUARY 18, 2021
Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.
The Pharma Data
MARCH 13, 2022
People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. The samples were stored after the researchers measured the T cell response. population.
The Pharma Data
DECEMBER 29, 2020
As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. Regeneron Pharmaceuticals, Inc. futility analysis). The results passed the futility analysis (p<0.3
Drug Discovery World
JULY 26, 2022
The talk will cover the technology behind the vaccine and the mechanisms of antibody and T cell immune responses triggered by the Covid-19 mRNA vaccine. . The lecture is one of a series of named lectures, organised by the LMB and given by eminent scientists from around the world. . Lecture abstract: .
Expert insights. Personalized for you.
52 
Let's personalize your content